Murine cytochrome P450 2A5 (CYP2A5) is an interesting enzyme for its unique regulation and its involvement in liver injury caused by various well-known pathological conditions or hepatotoxins. It has been reported that CYP2A5 is upregulated following exposure to chemical hepatotoxins and during pathophysiological conditions in which the levels of most Cytochrome P450s are either unchanged or down-regulated. Recently bilirubin has been identified as the first endogenous substrate for CYP2A5 and it has been suggested that CYP2A5 plays a major role in bilirubin clearance as an alternative mechanism to BR conjugation by UGT1A1. This study investigated the mechanisms of gene regulation and cytoprotective role of CYP2A5 in response to bilirubin treatment in liver. Our results demonstrate that bilirubin induces CYP2A5 expression at the mRNA and protein levels by increasing CYP2A5 transcription via a mechanism that involves Nrf2 activation. Furthermore, our results suggest that induced CYP2A5 plays a cytoprotective role against bilirubin toxicity by directly lowering the cellular levels of bilirubin and by inhibiting caspase-3 activation.

No description available.

The rise of large scale agriculture in the 20th century created the need for effective strategies to control insect pests. Treatment with chemical insecticides has been a weapon of choice, but the inevitable evolution of resistance has followed in many insect species. Resistance represents a major challenge, not only for agricultural production, but also for environmental preservation and human health. Two major options for resistance have been identified, and these are target-site based and metabolic-based resistance. Much insecticide resistance research focuses on identifying these mechanisms through genetic and molecular analysis. The insecticide lufenuron is the focus of this study. It belongs to a novel insecticidal group called the insect growth regulators, which were introduced in 1970s as highly selective insecticides with low vertebrate toxicity. Resistance to lufenuron in the non-pest species Drosophila melanogaster has been observed in field populations, despite the lack of field usage of lufenuron (Wilson & Cain, 1997; O’Keefe, 1997). This study has taken advantage of this phenomenon to investigate resistance mechanisms in natural populations. At least two detoxification mechanisms were identified. (For complete abstract open document)

Master of Philosophy / Clozapine is a drug of choice for treatment of refractory schizophrenia, which is primarily metabolized by Cytochrome P450 1A2 (CYP1A2). Norclozapine is its main metabolite. There are reports of wide ranging gastrointestinal side effects associated with clozapine therapy, that result in concomitant administration of proton pump inhibitors to treat acid-related disorders. Omeprazole is an established CYP1A2 inducer, while an in vitro study has shown that rabeprazole is much less potent in this regard. There is no available information about the impact of rabeprazole on CYP1A2 activity in patients. Firstly, this information is essential when prescriptions are changed from omeprazole to rabeprazole to reduce medication costs. Therefore, the aim of this study was to compare the effects of rabeprazole and omeprazole on CYP1A2-mediated clearance (CL/F) of clozapine. Secondly, the effective dosage of clozapine varies widely among patients, making it necessary to individualize drug therapy with clozapine. The reason for dosage variation could be due to the influence of patient-related variables on clozapine plasma concentrations. Therefore, another aim of this study was to investigate the relationship between patient variables, such as age, gender, cigarette smoke, weight and body mass index and clozapine clearance (CL/F). A cross-over study design was used for this study. Twenty patients from Macquarie hospital who were receiving clozapine and rabeprazole (with no other interacting medications) were recruited in this study. Blood samples were taken at 30 min, 1 hr, 2 hr and 12 hr after a dose of clozapine. Rabeprazole was then replaced with omeprazole. After at least 1 month blood samples were again collected at the above corresponding intervals after clozapine. The plasma concentrations of clozapine and norclozapine were determined by high performance liquid chromatography. Abbottbase Pharmacokinetic Systems Software, which utilizes Bayesian forecasting, was used to estimate pharmacokinetic parameters of clozapine. The ratio of plasma norclozapine/clozapine concentrations at trough level was used to reflect CYP1A2 activity. No difference was observed in clozapine clearance (CL/F) and CYP1A2 activity during concurrent therapy with either rabeprazole or omeprazole. According to some studies CYP1A2 induction by omeprazole is dose dependent. Furthermore, since rabeprazole is a weak CYP1A2 inducer in vitro, we conclude that omeprazole and rabeprazole may not induce CYP1A2 activity when used at conventional therapeutic dosage (<40 mg/day). Hence, replacement of omeprazole with rabeprazole at conventional therapeutic dosages (20 or 40 mg daily) offers no advantages in the management of patients with schizophrenia on clozapine and no dose adjustment is required. Consistent with previous studies, clozapine concentrations were found to be significantly lower in cigarette smokers due to CYP1A2 induction. No relationship was found between age, gender, or weight and clozapine clearance (CL/F). However, body mass index showed a significant negative correlation with clozapine clearance (CL/F). Since weight gain and lipid accumulation are common side effects of clozapine they may be associated with a reduction of CYP1A2 activity and clozapine clearance (CL/F). Moreover, high lipoprotein levels may decrease the unbound fraction of clozapine and decrease the availability of clozapine for oxidation by cytochrome P450 enzymes. Therefore, it is concluded that omeprazole and rabeprazole may not induce CYP1A2 activity when used at conventional therapeutic dosage (<40mg/day). Hence, replacement of omeprazole with rabeprazole does not require the dose of clozapine to be adjusted. Moreover, the negative correlation between clozapine clearance (CL/F) and BMI is informative. Further studies are now required to clarify the relationship between BMI, lipoprotein levels and clozapine clearance in patients with schizophrenia.

Mémoire numérisé par la Direction des bibliothèques de l'Université de Montréal.

Abstract Cytochromes P450 (P450, CYP) are a superfamily of enzymes that participate especially in the oxidative metabolism of various xenobiotics and endogenous compounds. The major goal of this study was to characterise suitable methods for routine preclinical in vitro testing of new chemical entities (NCE) and to test the methods for the affinity screening of selected drugs. In vitro methods used involve the utilisation of human liver microsomes for studies with P450-selective reference inhibitors, inhibitory antibodies and cDNA-expressed enzymes in cytochrome P450-catalysed activities and for studying the reactions of selegiline and entacapone. In this project, the CYP-catalysed oxidative in vitro biotransformation of selegiline into its primary metabolites desmethylselegiline and l-methamphetamine and the transformation of entacapone into its in vitro metabolite N-desethylentacapone were studied. The affinities of selegiline, desmethylselegiline, l-methamphetamine, entacapone, candesartan, eprosartan, irbesartan, losartan and valsartan to P450 enzymes were also elucidated, and the selectivity of tranylcypromine as a CYP2A6-selective reference inhibitor was characterised. The most important findings were that the methodology developed during this work is suitable for preclinical in vitro testing of NCEs and that the results obtained for the studied compounds are in line with the available in vivo data. By the in vitro testing methodology, it is possible to target the in vivo interaction studies to the relevant groups of compounds. The in vitro methods presented in this thesis could also make the early phases of drug development more cost-effective. Further, the number of animals used for in vivo testing in preclinical metabolism and interaction studies can be markedly reduced by effectively using this methodology.

The biophysical and spectroscopic characterisation of two novel P450 fusion enzymes is reported. The first of these is CYP102A3, which is a fusion of P450 haem and cytochrome P450 reductase (CPR)-like domains and functions as a catalytically self-sufficient fatty acid hydroxylase in its host organism Bacillus subtilis. The elucidation of structural aspects of the isolated haem domain of CYP102A3 (HDCYP102A3) is described. This reveals a strong homology between HDCYP102A3 and the haem domain of the related, well studied enzyme CYP102A1 (known as BM3). Examination of the substrate binding and redox properties of HDCYP102A3 reveals variations in substrate selectivity and the influence of substrate binding over the haem-iron redox potential compared to BM3. Of particular note is the apparent cooperative binding profile displayed for some branched chain fatty acid substrates with CYP102A3. The second system characterised is CYP116B1 from Cupriavidus metallidurans, a P450 fusion with a reductase domain that resembles phthalate dioxygenase reductase (PDOR). The purification of the intact CYP116B1 enzyme, and also of its isolated haem domain (expressed from the relevant gene section), is optimised and biophysical characterisations are reported. The haem iron redox potential is found to be unusually positive (-85 mV) and the influence of thiocarbamate herbicide substrate binding upon this potential is found to be minimal, unlike the case in CYP102A£ with its fatty acid substrates and likely as a consequence of the relatively small degree of shift in haem-iron spin-state towards the high-spin form. From a panel of eight potential substrates for CYP116B1, six were found to stimulate NADPH oxidation, but only two of these were themselves oxidised by the enzyme, with hydroxylated products observable. The genetically dissected reductase domain of CYP116B1 was also expressed and purified, and kinetic studies of the reductase domain revealed a preference for NADPH over NADH coenzyme, and enables comparisons with kinetic features and coenzyme selectivity in other members of the ferredoxin reductase family of enzymes. Collectively, these studies advance our knowledge of the properties of two distinct types of P450-redox partner fusion enzymes, a growing class of enzymes with potential for biotechnological applications.

Campylobacter jejuni is a leading cause of food poisoning and according to the World Health Organisation accounts for majority of the 4.5 billion cases of global food poisoning each year. Genome sequencing by Parkhill et al. (2000) identified a gene, cj1411c, which is thought to encode a lone cytochrome P450, CYP172A1. In this thesis the role of CYP172A1 was studied using in vivo and in vitro techniques. The genomic location of cj1411c is adjacent to the capsular biosynthetic genes. The capsular and P450 genes are conserved in some species of Campylobacter and Helicobacter, as well as in Comamonas testosteroni. Importantly, this work has demonstrated that the P450 gene is expressed in two well characterised laboratory C. jejuni strains, 11168H and 81-176. Protein production was disrupted using insertional knockout mutagenesis, which allowed for investigations into the role of the enzyme in the host. Alterations to the observed autoagglutination rate and growth characteristics indicated that CYP172A1 has a role in modifying the bacterial surface. The insertional knockout mutant also resulted in cells which were more susceptible to detergent-like compounds (e.g. polymyxin B and sodium deoxycholate). In a previous report, it was suggested that the loss of the P450 function resulted in bacteria which were “shorter and fatter”, compared to wild type cells, but this thesis could find no evidence of such a phenomenon. CYP172A1 was successfully purified using recombinant expression in E. coli to enable biochemical and biophysical characterisation in vitro. CYP172A1 contains a typical P450 cysteine thiolate coordination to the heme iron, and exists in a low spin ferric heme state under neutral buffer conditions. The P450 was found to self aggregate, and despite rigorous investigations the cause of this aggregation was not fully established. Despite this issue, CYP172A1 was shown to bind to a wide range of P450 inhibitor-type compounds, with econazole displaying the tightest binding affinity (Kd = 100 nM). Identification of substrate-like compounds was achieved using high throughput compound screening, and a number of organic compounds were identified and shown to bind CYP172A1, inducing heme iron absorbance changes typical of either P450 inhibitors or substrates. Optical titrations for these molecules indicated that their CYP172A1 Kd values were in the low micromolar range. The catalytic capability of CYP172A1 was successfully demonstrated by providing the P450 with non native redox partners to oxidise one of such substrate-like compound (213071), resulting in the sulfoxidation of this compound.

Cytochrome P450 (P450) enzymes are found in all kingdoms of life, catalysing a wide range of biosynthetic and metabolic processes. They are, in fact, of particular interest in a variety of applications such as the design of agents for the inhibition of a particular P450 to combat pathogens or the engineering of enzymes to produce a particular activity. Bacterial P450BM3 is of particular interest as it is a self-sufficient multi-domain protein with high reaction rates and a primary structure and function similar to mammalian isoforms. It is an attractive enzyme to study due to its potential for engineering catalysts with fast reaction rates which selectively produce molecules of high value.In order to study this enzyme in detail and characterise intermediate species and reactions, the first step was to design a general hybrid quantum mechanical /molecular mechanics (QM/MM) computational method for their investigation. Two QM/MM approaches were developed and tested against existing experimental and theoretical data and were then applied to subsequent investigations.The dissociation of water from the water-bound resting state was scrutinised to determine the nature of the spin conversion that occurs during this transformation. A displacement of merely 0.5 Å from the starting state was found to trigger spin crossing, with no requirement for the presence of a substrate or large conformational changes in the enzyme.A detailed investigation of the sulfoxidation reaction was undertaken to establish the nature of the oxidant species. Both reactions involving Compound 0 (Cpd0) and Compound I (CpdI) confirmed a concerted pathway proceeding via a single-state reactivity mechanism. As the reaction involving Cpd0 was found to be unrealistically high, the reaction proceeds preferentially via the quartet state of CpdI. This QM/MM study revealed that the preferred spin-state and the transition state structure for sulfoxidation are influenced by the protein environment. P450cam and P450BM3 were found to have CpdI species with different Fe-S distances and spin density distributions, and the latter having a larger reaction barrier for sulfoxidation.A novel P450 species, the doubly-reduced pentacoordinated system, was characterised using gas-phase and QM/MM methods. It was discovered to have a heme radical coupled to two unpaired electrons on the iron centre, making it the only P450 species to have similar characteristics to CpdI. Calculated spectroscopic parameters may assist experimentalists in the identification of the elusive CpdI.

The objective of this study was to examine hepatic steroid inactivation and luteal function throughout bovine gestation. In pregnant beef cows, cytochrome P450 3A activity decreased from mid- to late-gestation, while progesterone concentrations tended to increase from mid- to late-gestation. Uridine diphosphate-glucuronosyltransferase activity per kg of body weight was increased in pregnant vs non-pregnant dairy cows. Total corpus luteum (CL) blood perfusion tended to be increased in pregnant vs non-pregnant dairy cows. Hepatic portal blood flow per kg of body weight was increased in pregnant vs non-pregnant dairy cows. Hepatic steroid inactivating enzyme activity, CL blood perfusion, and portal blood flow did not differ between pregnant and non-pregnant beef cows. There was no difference in progesterone concentrations in pregnant vs non-pregnant dairy or beef cows. The current study highlights the relevance of further investigation into steroid secretion and inactivation and their impact on the maintenance of pregnancy in cattle.